Related Experiment Videos
[Secondary prevention in chronic coronary heart disease]
1Medizinische Klinik, Stadtspital Triemli, Zürich.
Insights
Secondary prevention for coronary artery disease (CAD) is underutilized. Patients receiving invasive treatment showed better adherence to beneficial medications like aspirin and beta-blockers compared to others.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Research
Background:
- Coronary artery disease (CAD) management requires effective secondary prevention strategies.
- Acute coronary syndromes (ACS) necessitate timely and appropriate medical interventions.
- Assessing the quality of secondary prevention in known CAD patients is crucial for improving outcomes.
Purpose of the Study:
- To evaluate the current quality of secondary prevention in patients hospitalized for acute coronary syndromes with known CAD.
- To identify disparities in medication use among different patient subgroups within the CAD population.
Main Methods:
- Prospective analysis of 278 consecutive patients admitted for acute coronary syndromes.
- Detailed review of medical history, including known CAD and previous interventions.
- Assessment of medication administration rates for key secondary prevention drugs (aspirin, anticoagulants, beta-blockers, ACE inhibitors, lipid-lowering agents).
Main Results:
- Only 58% of patients with known CAD received aspirin, 43% beta-blockers, and 12% lipid-lowering agents.
- Patients with prior invasive diagnosis and treatment demonstrated significantly higher rates of aspirin (78%), beta-blocker (59%), and lipid-lowering drug (27%) use.
- Despite proven benefits, only one-fourth of dyslipidemic patients were prescribed lipid-lowering drugs.
Conclusions:
- The prevalence of secondary prophylaxis in patients with known CAD is suboptimal.
- Invasively treated patients receive superior secondary prevention compared to those without invasive procedures.
- There is a significant need to improve the implementation of evidence-based secondary prevention strategies in CAD patients.
Abstract:
To assess the quality of secondary prevention in patients with known coronary artery disease (CAD) we analyzed prospectively 278 consecutive patients on admission who were hospitalized for acute coronary syndromes (infarction 46%, unstable angina 54%). CAD was known in 155 patients (110 males: acute myocardial infarction 50, unstable angina 105; history of infarction 55%, chronic angina 41%, after CABG 13%, after PTCA 7%, coronary stenoses on angiography 6%). In these patients, aspirin was being administered in 58%, anticoagulation in 12%, betablockers in 43%, angiotensin converting enzyme inhibitors (ACEI) in 20%, and lipid lowering agents in 12%. Calcium blockers were given in 40% (nifedipine 8%). Patients with previous invasive diagnosis and treatment were more frequently treated with drugs of proven prognostic benefit than patients after myocardial infarction and patients with angina only, while overall cardiovascular treatment was similar. The respective rates of treatment were: for aspirin 78%, 60% and 39% respectively (p = 0.0005); for betablockers 59%, 46% and 24% (p = 0.004); for lipid lowering drugs 27%, 7% and 4% (p = 0.002). 12 of 19 patients with known congestive heart failure had ACEI. Only one fourth of dyslipidemic patients had lipid lowering drugs. We conclude that the prevalence of secondary prophylaxis in patients with known CAD is too low despite proven benefit, invasively treated patients having better prophylaxis.